French Cannabis Media Outlet Newsweed reports
French patients taking part in the country’s medical cannabis experiment are to lose their supply of pharmaceutical CBD oil, as Little Green Pharma pulls out.
Reports from French cannabis media site, Newsweed, regarding a possible shortage of products in the country’s medical cannabis trial, have now been confirmed in communication with stakeholders.
Last year the National Agency for the Safety of Medicines and Health Products (ANSM) announced an extension to its medical cannabis experiment, which allows up to 3,000 patients to access free medicinal cannabis, to evaluate how products could be prescribed and dispensed legally in France.
However, the experiment is expected to lose its supply of (non-THC) pharmaceutical CBD oil from Little Green Pharma, which represented around 60% of the products prescribed.
According to information from Newsweed, the manufacturer does not wish to continue to offer its product for free or at €14 per bottle – a price well below its production, transport and customs costs – as proposed by the Ministry of Health for the extension of the experiment.
The advice for patients on the scheme who are currently being treated with this product are to replace it with the following:
- Epidyolex for children with epilepsy whose condition is stabilised
- A CBD:THC 20:1 oil for adults with spasticity and/or multiple sclerosis
Adult patients who have found success with a pure CBD oil are being advised to change treatment and experiment with a product containing THC, which some may not know how to tolerate.
Read more at
France’s medical cannabis experiment facing shortage of CBD oil
